Stock Market Soars After First COVID-19 Vaccine Tested in U.S. Produced Antibodies in All Patients During Trial | Beaufort County Now | Stocks soared Wednesday following news that a new COVID-19 vaccine showed that it produced antibodies in all patients during a trial. | daily wire, stock market, coronavirus, covid-19, vaccine test, antibodies, july 15, 2020

Coronavirus Disease 2019 (COVID-19)

Stock Market Soars After First COVID-19 Vaccine Tested in U.S. Produced Antibodies in All Patients During Trial

Publisher's note: This post appears here courtesy of the The Daily Wire, and written by Joseph Curl.

    Stocks soared Wednesday following news that a new COVID-19 vaccine showed that it produced antibodies in all patients during a trial.

    Even before the opening gavel fell, stock futures rose more than 500 points. When the market opened at 9:30 a.m., the Dow settled in, rising in the mid-300s.

    The stock surge followed news from Moderna, a pharmaceutical company that announced Tuesday night that its coronavirus vaccine produced a "robust" immune response — meaning antibodies — in all 45 patients in its early stage human trial, according to data published in the peer-reviewed New England Journal of Medicine.

    "No matter how you slice this, this is good news," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told The Associated Press.

    "The hallmark of a vaccine is one that can actually mimic natural infection and induce the kind of response that you would get with natural infection. And it looks like, at least in this limited, small number of individuals, that is exactly what's happening," Fauci said. "The data really look quite good. There were no serious adverse events."

    The Moderna vaccine test began back in March, with 45 volunteers being injected twice, a month apart. Every one of the test subjects developed "neutralizing" antibodies in their bloodstream at levels about the same as people who had contracted COVID-19 and recovered, the Journal reported.

    "This is an essential building block that is needed to move forward with the trials that could actually determine whether the vaccine does protect against infection," said Dr. Lisa Jackson of the Kaiser Permanente Washington Research Institute in Seattle, who led the study.

    There were no serious side effects, the researchers said, but about half of the volunteers did report flu-like reactions, including headache, fatigue, chills, fever, and pain at the injection site. For those who suffered fever, it lasted just a day.

    Other COVID-19 vaccines are moving swiftly as well.

    Pfizer has teamed with Germany-based BioNTech, a smaller company with experience in working with RNA vaccines, and conducted initial trials. Those who received a small first dose had nearly double the number of antibodies as those who had recovered from the virus, while those who received larger dose had triple the number of antibodies. After a second dose, the small-dose test group had eight times the antibodies, while the large dose group had 50 times the antibodies.

    Pfizer has said they hope to have approval from the U.S. Food and Drug Administration by October.

    Oxford is much farther ahead, now conducting Phase III trials in Brazil, South Africa, and the United Kingdom. The U.S. is set to be added in August with patients in 33 spots around the nation.

    Oxford is even more optimistic than Pfizer, saying they could have results from the trials by the end of August and be ready to move forward with a vaccine in September. Its partner, AstraZeneca, is already producing the vaccine and the company recently said it plans to create 2 billion doses, some 400 million by the end of 2020.


Latest Op-Ed & Politics

Sherry-Lynn Womack finds herself in the proverbial hot water. Her crime? Womack went up to Washington, D.C., for the rally for Donald Trump on Jan. 6.
The year ended with a record-breaking $3.1 trillion deficit and, as usual, the U.S. government managed to blow tens of billions on a myriad of wasteful projects that should provoke outrage among tax-paying Americans.
House Speaker Nancy Pelosi (D-CA) will deliver an article of impeachment against former President Donald Trump to the Senate on Monday, Senate Majority Leader Chuck Schumer announced Friday.
Protecting the Club is more important than standing on principle
It’s so easy to let jealousy trump good sense. I think that’s what a ‘wealth tax’ is all about.
In this installment, we will discuss the "controversial" Gospel of Judas and how it can be used to decipher cryptic messages made by actors portraying the role of "Judas" in the current political arena..
The North Carolina Council on Health Care Coverage held its last meeting today to finalize principles to help guide Governor Roy Cooper and legislative leaders as they consider options to increase affordable and comprehensive health coverage for North Carolinians.


At the Request of President Biden, Acting Secretary of Education Will Extend Pause on Federal Student Loan Payments
She's impressive and hopefully isn't finished in public service.
Chicago prosecutors say 36-year-old Aditya Singh lived in the city’s O’Hare International Airport for three months to avoid flying home to Los Angeles, California, amid the coronavirus pandemic.
Are you spending your precious time wisely, or are you a pawn, an infinitesimal cog, in someone else's Global Plan?
As of Jan. 18, North Carolina had received about a million doses of COVID-19 vaccines.
Come with us on Part II of Wolfman and The Guardians' journey through the streets of our nation's capitol. These stories are only available exclusively here at BCN!
Joy Pullmann of the Federalist explains how right-of-center partisans can respond well to a Biden presidency.


Back to Top